Pharmaceutical Combination for Use in Glycemic Control in Diabetes Type 2 Patients

Abstract

The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.

1 . A method for improvement of glycemic control in a patient with type 2 diabetes mellitus, the method comprising administering to the patient a treatment comprising a combination of:
 (a) lixisenatide, and   (b) a glitazone;   
       wherein the patient is inadequately controlled by treatment with the glitazone. 
     
     
         2 . A method for improvement of glycemic control in a patient with type 2 diabetes mellitus, the method comprising administering to the patient a treatment comprising a combination of:
 (a) lixisenatide;   (b) a glitazone, and   (c) metformin;   
       wherein the patient is inadequately controlled by treatment with the glitazone and metformin. 
     
     
         3 . The method of  claim 1  or  2 , wherein the glitazone is pioglitazone. 
     
     
         4 . The method of  claim 1  or  2 , wherein the lixisenatide is administered once per day at a dose of 10 μg to 20 μg. 
     
     
         5 . The method of  claim 1 , wherein the patient has a hemoglobin A1c (HbA 1c ) value of at least 8% and a fasting plasma glucose of at least 9 mmol/L when treated with the glitazone. 
     
     
         6 . The method of  claim 2 , wherein the patient has a hemoglobin A1c (HbA 1c ) value of at least 8% and a fasting plasma glucose of at least 9 mmol/L when treated with the glitazone and metformin. 
     
     
         7 . A method for improving glycemic control in a type 2 diabetes mellitus patient receiving treatment with a glitazone, the method comprising administering lixisenatide as an add-on treatment to the patient. 
     
     
         8 . The method of  claim 7 , wherein the patient is receiving treatment with a glitazone and further metformin. 
     
     
         9 . The method of  claim 7 , wherein the glitazone is pioglitazone. 
     
     
         10 . The method of  claim 7 , wherein the lixisenatide is administered once per day at a dose of 10 μg to 20 μg.